medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2011, Number 1

<< Back Next >>

VacciMonitor 2011; 20 (1)

Immunomodulator effect of the CM-95 Solution treated magnetically in Balb/c mouse with 5- fluorouracil inoculated

Martínez C, Tamayo V, Favier P, Reynier CJ, Hernández R, Sierra G

Language: Spanish
References: 39
Page: 13-21
PDF size: 341.40 Kb.


ABSTRACT

5-Fluorouracil is an antineoplastic drug used in cancer chemotherapy. It has immunosuppressant effects by inhibiting cell proliferation from the haematopoietic tissue. In this paper, the immunomodulating effect of the magnetically treated CM-95 solution in Balb/c mice inoculated with 5- fluorouracil by its rehabilitating protecting action on cell parameters of the haematopoietic tissue. Six-week old mice weighing 20-22 g were inoculated twice with magnetically treated CM-95 solution by intraperitoneal route. Then, they received 5-fluoracile in a dose of 150 mg/m2 of body surface by the same route. Haematopoietic parameters such as total and differential leukocyte count were evaluated before applying the antineoplastic drug and at the third and seventh days after the application. Bone marrow and spleen cellularity as well as the microscopic observation of the histological cut of the liver and of spleen, by the technique of inclusion in paraffin dyes with 10% eosin haematoxylin, were evaluated at seven days after the application of 5 fluorouracil. The magnetically treated CM-95 solution could modulate the effects of 5-fluorouracil with protecting and rehabilitating activity for the parameters evaluated in the bone marrow, peripheral blood, spleen and liver. These results open new perspectives for the application of the magnetically treated aqueous system as immunomodulator.


REFERENCES

  1. Ignacio Melero. Desarrollo de nuevas estrategias moleculares de inmunoterapia frente a enfermedades malignas. Simposio Internacional de Inmunología e Inmunoterapia del Cáncer; 2007 enero 16-17. Pamplona, España: Centro de Investigación Médica Aplicada (CIMA). Universidad de Navarra, Fundación Ramón Areces; 2007.

  2. Klassem VJ. Magnetización de sistemas acuosos. Moscú: Editorial Química;1982 .

  3. Polk C, Pastow E. Handbook of Biological. Effects of Electromagnetic Field. Boca de Ratón. CRC: Edition Press II; 1986.

  4. Zhadin MN. Review of Russian literature on Biological action of DC and low frequency AC magnetic field. Biolelectromagnetics 2001; 22 (1):27-47.

  5. Manni V, Antonella L, Pozzi P, Riete S, Serafino A, Grimaldi S. Effects estremely low frecuency 50 Hz magnetic field on morphological and biochemical properties of human keratinocytes. Bioelectromagnetics 2002;23(4):298-315.

  6. Martínez C, Portuondo I, Infante JF, Sierra G, Delgado L, Cobas G, et al. Evaluación de la sustancia CM-95 tratada magnéticamente como inmunopotenciador con antígenos particulados en ratones de la línea Balb/c por vía intraperitoneal. Vaccimonitor 1999;8 (11):2-6.

  7. Martínez CE, Cobas G, Lebeque Y, Fontaine R, Pérez I, Morris H, et al. Evaluación de la sustancia CM-95 tratada magnéticamente como inmunopotenciador con antígenos de Pseudomonas aeruginosa. Biotecnología Aplicada 2003; 20:22-5.

  8. Martínez CE, Pérez I, Fontaine R, Morris H. Efectos de la Solución CM-95 tratada magnéticamente sobre células mononucleares en ratones Balb/c. Biotecnología Aplicada 2004;21:224-8.

  9. Canadian Council on Animal Care (CCAC). Hematology and Clinical Biochemistry Reference Values. In: Guide to the care and use of experimental animals. Ottawa (Canadá): CCAC Publishing House;1984. p. 86-8

  10. Martínez CE, Rodríguez B, Cobas G, Hurtado A, Pérez I, Correa M. Solución adyuvante. Patente Cubana CU 22583, 114.1999. Julio 19.

  11. Colina JA, Álvarez RE, Celso Rc, Ballester JS, Ballester SA, Hernández G, et al. Laboratorio. Tomo I. Ciudad de La Habana: Editorial Pueblo y Educación;1989.

  12. Hernández SE. Efecto del extracto acuoso de Trichilia hirta en la mejoría de pacientes neoplásicos [Trabajo de Diploma]. Departamento Biología. Facultad de Ciencias Naturales. Universidad de Oriente. Santiago de Cuba. Cuba; 2004.

  13. Infante JF, Pérez PS, Infante JF. Neisseria meningitides. Resultados experimentales sobre los biomodelos de rata ratón. Monografía F. D. Ciudad de La Habana: Editorial Finlay Ediciones; 1996.

  14. Díaz BJ, Martínez CE, Alfonso CA, Pardo TA, Esmérido BJ, Salas MH, Et al. Evaluación de la toxicidad aguda oral e irritación sobre mucosa bucal de la Solución CM-95 tratada magnéticamente. Acta Toxicol 2008;16(2):34-40.

  15. Abbas Ak, Lichman AH, Pober JS. Inmunología Celular y Molecular. 3ra edición. Madrid, España: McGraw-Hill Interamericana; 2000.

  16. Anónimo 1.5- fluorouracilo. Disponible en http:// es.wikipedia.org/wiki/5-fluorouracilo. [Consultado: 15 Diciembre, 2009].

  17. 17- Blank M, Goodman R. Do electromagneticic field interaction directly with DNA?Bioelectromagnetics 1997;18:111-5

  18. Rodríguez B, Correa M, Hurtado A. Efectos del tratamiento magnético del agua y Soluciones acuosas. Rev Cub Quím 1998;10 (3):1-2.

  19. Martínez MC, Tamayo O V, Sierra GG. Obtención del suero anti IgG humano con la solución CM-95 tratada magnéticamente como adyuvante inmunológico. MEDISAN 2007;11(4). Disponible en: http://bvs.sld.cu/revistas/san/vol11_4_07/ san09407.htm [consultado: Junio, 2009].

  20. Martínez CE, Toledano M, Rodríguez G, Keagne A, Iztiz L, Sierra G. Solución adyuvante CM-95 tratada magnéticamente en comparación con el adyuvante de Freund para la obtención del suero de Coombs en conejo. Vaccimonitor 2009;18(3): 5-12.

  21. O’Hagan D, Valiante NM. Recent advances in the discovery and delivery of vaccine adjuvants. Nature Rev 2003;2: 727–35.

  22. Infante JF, Sifontes S, Pérez V, Bracho G, Hernández T, Zayas C, et al. Ensayo de inmunogenicidad y de toxicidad local del cocleato de Neisseria meningitidis en ratas Spregue Dawley. VacciMonitor 2009; 18(1):1-7.

  23. Fujihashi K, Koga T, van Ginkel FW, Hagiwara Y, McGhee J R A dilemma for mucosal vaccination efficacy versus: toxicity using enterotoxin- based adjuvants. Vaccine 2002; 20:2431–38.

  24. Gizurarson S, Georgsson G, Aggerbeck H, Thorarinsdóttir H and Heron I. Evaluation of local toxicity after repeated intranasal vaccination of guinea-pigs. Toxicology 1996; 107(1): 61-8.

  25. Hardegree MC. and Pittman M. Influence of antigens on release of fatty acids from Arlacel A (mannide monooleate). Proc. Soc. Exp. Biol. Med 1966;123:79.

  26. Sun HX, Xie Y, Ye Y. Advances in saponin-based adjuvants. Vaccine 2009; 27: 1787-96.

  27. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N Engl J Med 2004; 350: 896-903.

  28. Harkema JR. Comparative pathology of nasal mucosa in laboratory animals exposed to inhaled irritants. Environ Health Perspective 1990;85: 231-8.

  29. Balls M. The EC/HO international validation study on alternatives to the Draize eye irritation test. Toxicology in vitro 1995; 9:871-929.

  30. Ying Y, Xinfeng Y, Wengai Z, Jinheng C, Jinyu X, Guangyu Y, et al. Combinated in vitro test as an alternative to in vivo eye irritation tests. ATLA 2010;38: 303-14.

  31. Doty RL, Cometto-Muñiz E, Jalowayski A, Dalton P, Kendal- Reed M, Hodgson M. Assessment of Upper Respiratory Tract and Ocular Irritative Effects of Volatile Chemicals in Humans. Crit Rev Toxicol, 2004; 34(2): 85–142.

  32. Spielmann H. HET-CAM Test. The ERGATT/FRAME. Databank of in vitro techniques. INVITTOX 1992; IP-47: 1-9.

  33. Balls M Animal experimentation and the three Rs: past, present and future. ATLA 2009; 37, suppl2:1-6.

  34. Djabari Z, Bauza E, Dal Farra C, Domloge N The HET-CAM test combined with histological studies for better evaluation of active ingredient innocuity. Int J Tissue React. 2002;24(4):117- 21.

  35. Murillo G, Pérez U, Tur E, Vinardell P, García G, Pascual J. Estudio comparativo de tres variantes del ensayo de la membrana corioalantoidea del huevo de gallina para la evaluación de la irritabilidad ocular. Rev Toxicol 2003;20:187- 92.

  36. Pérez O, Bracho G, Lastre M, et al. Método de obtención de estructuras cocleares. Composiciones vacunales y adyuvantes basados en estructuras cocleares y sus intermediarios. 2002 Patent application Cu 2002–0292.

  37. Brennan F, Dougan G. Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies. Vaccine 2005;23:3210–22.

  38. Seppic. MontanideTM IMS: An innovative range of adjuvants for vaccines and injectables. P/0891/GB/03/November 2002. France: www.seppic.com.

  39. Batista A, Quattrocchi V, Olivera C, Langellotti C, Pappalardo J, Di Giacomo S. et al. Adjuvant effect of CliptoxTM on the protective immune response induced by an inactivated vaccine against foot and mouth disease virus in mice. Vaccine 2010;28: 6361–66.




2020     |     www.medigraphic.com